HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety - Richardson, P G; Oriol, A; Larocca, A (Clin Lymph Myelom Leukem, 2019)
et al.